- About half of the people treated for melanoma will have a recurrence.
- Researchers recently presented phase 2b clinical trial results showing a combination of an mRNA vaccine and immunotherapy helps reduce the likelihood of melanoma recurrence in people who had surgery to remove melanoma from lymph nodes or other organs.
- The researchers combined the experimental vaccine mRNA-4157/V940 and the immunotherapy pembrolizumab in patients with melanoma.
In 2020, almost 325,000 people globally were diagnosed with melanoma — a type of skin cancer.
Previous research says the number of people with melanoma will
Past studies show about half of people treated for melanoma will have a
Researchers recently presented phase 2b clinical trial results at the annual meeting of the American Association for Cancer Research, showing a combination of an experimental mRNA vaccine with
The clinical trial was funded by Moderna Inc., which makes the experimental vaccine mRNA-4157/V940, and Merck, which manufactures the immunotherapy drug
Melanoma is a type of skin cancer that can occur anywhere on the body’s skin. The cancer develops when human skin cells called
The most common cause of melanoma is exposure to
People at risk for melanoma tend to have a fair complexion that burns easily. Other melanoma risk factors include:
There are five stages of melanoma, starting at Stage 0 where the cancer is only present in the outermost skin layer, and up to Stage 4 where the cancer has spread to other parts of…
Read the full article here